VALENCIA, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) — Nusano, a physics company transforming the production of radioisotopes, today announced the company’s CEO Chris Lowe will present at Piper Sandler’s Next-Gen RadioPharma Symposium virtual event on Thursday, Jan. 23, 2025. The fireside chat-style presentation will highlight Nusano’s 2025 commercialization plans and provide an overview of how the company will leverage its proprietary technologies to make new supplies of rare and hard-to-produce radioisotopes available for medical and commercial markets.
| WHO: | Nusano CEO Chris Lowe |
| WHAT: | Fireside chat |
| WHEN: | Thursday, Jan. 23, 2025 2:00 – 2:25 PM Eastern |
| WHERE: | Virtual Event – Piper Sandler Next-Gen RadioPharma Symposium |
To listen to the webcast, please contact your representative at Piper Sandler and request a link.
About Nusano
Nusano is a privately held physics company committed to bringing supply stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market, and to serving industrial and commercial markets dependent on reliable access to high quality radioisotopes for their products and services. Driven by the company’s proprietary ion source, the Nusano production platform will generate radioisotopes in volumes and varieties exceeding other production methods. Nusano’s breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. For more, please visit nusano.com.
Contacts:
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…